74103-06-3
74103-06-3
Chemical Structure
Ketorolac
Synonym(s): RS37619
- CAS No.: 74103-06-3
- Formula:C15H13NO3
- Molecular Weight:255.27
IUPAC Name: 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
InChIKey: OZWKMVRBQXNZKK-UHFFFAOYSA-N
SMILES: O=C(C1C2=CC=C(C(C3=CC=CC=C3)=O)N2CC1)O
Biological Activity: Ketorolac (RS37619) is a non-steroidal anti-inflammatory drug (NSAID), acting as a nonselective COX inhibitor, with IC50s of 20 nM for COX-1 and 120 nM for COX-2. Ketorolac tromethamine is used as 0.5% ophthalmic solution for the research of allergic conjunctivitis, cystoid macular edema, intraoperative miosis, and postoperative ocular inflammation and pain. Ketorolac tromethamine is also a DDX3 inhibitor that can be used for cancer research[1][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ketorolac | 99.87% | Ketorolac (RS37619) is a non-steroidal anti-inflammatory drug (NSAID), acting as a nonselective COX inhibitor, with IC50s of 20 nM for COX-1 and 120 nM for COX-2. Ketorolac tromethamine is used as 0.5% ophthalmic solution for the research of allergic conjunctivitis, cystoid macular edema, intraoperative miosis, and postoperative ocular inflammation and pain. Ketorolac tromethamine is also a DDX3 inhibitor that can be used for cancer research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ketorolac (Standard) | 99.69% | Ketorolac (Standard) is the analytical standard of Ketorolac. This product is intended for research and analytical applications. Ketorolac (RS37619) is a non-steroidal anti-inflammatory drug (NSAID), acting as a nonselective COX inhibitor, with IC50s of 20 nM for COX-1 and 120 nM for COX-2. Ketorolac tromethamine is used as 0.5% ophthalmic solution for the research of allergic conjunctivitis, cystoid macular edema, intraoperative miosis, and postoperative ocular inflammation and pain. Ketorolac tromethamine is also a DDX3 inhibitor that can be used for cancer research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ketorolac-d5 | 98.31% | Ketorolac-d5 is a deuterium labeled Ketorolac. Ketorolac is a non-steroidal anti-inflammatory agent, acting as a nonselective COX inhibitor, with IC50s of 20 nM for COX-1 and 120 nM for COX-2. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ketorolac-13C6 | Ketorolac-13C6 (RS37619-13C6) is 13C labeled Ketorolac. Ketorolac (RS37619) is a non-steroidal anti-inflammatory drug (NSAID), acting as a nonselective COX inhibitor, with IC50s of 20 nM for COX-1 and 120 nM for COX-2. Ketorolac tromethamine is used as 0.5% ophthalmic solution for the research of allergic conjunctivitis, cystoid macular edema, intraoperative miosis, and postoperative ocular inflammation and pain. Ketorolac tromethamine is also a DDX3 inhibitor that can be used for cancer research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ketorolac-d4 | Ketorolac-d4 (RS37619 D4) is the deuterium labeled Ketorolac. Ketorolac is a non-steroidal anti-inflammatory agent, acting as a nonselective COX inhibitor, with IC50s of 20 nM for COX-1 and 120 nM for COX-2. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Anirolac | 97.0% | Anirolac (RS37326) is a nonsteroidal anti-inflammatory agent with analgesic activity. Anirolac showed analgesic efficacy comparable to that of naproxen in suppressing moderate or severe postpartum uterine pain. Anirolac induced significantly higher analgesia scores than placebo within 6 hours, especially at the 100 mg dose. Anirolac effectively relieved pain and showed a stronger analgesic effect than placebo in every assessment. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Nepafenac-d5 | 98.84% | Nepafenac-d5 (AHR-9434-d5; AL-6515-d5) is the deuterium labeled Nepafenac (HY-17357). Nepafenac, a nonsteroidal anti-inflammatory agent, is a topically administered COX-2 inhibitor with an IC50 of 0.12 μM. Nepafenac exhibits only weak COX-1 inhibitory activity (IC50 = 64.3 μM). Nepafenac possesses unique prodrug properties, which enable it to rapidly convert into the active metabolite Amfenac (HY-17479) in the ocular tissues, thereby achieving high concentrations in the retina and choroid. Nepafenac reduces inflammation and pain by inhibiting the activity of cyclooxygenase (COX) enzymes and thereby decreasing the production of prostaglandin PGE₂. Nepafenac can delay the metastasis of uveal melanoma (UM) in rabbit eyes. Nepafenac is mainly used for pain management and inflammation control after ophthalmic surgeries. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Amfenac-d5 | Amfenac-d5 is the deuterium labeled Amfenac. Amfenac is an orally active and potent anti-inflammatory compound possessing antipyretic and analgesic properties. Amfenac can be used for the research of acute and chronic inflammation. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ketorolac tromethamine salt (Standard) | 99.85% | Ketorolac (tromethamine salt) (Standard) is the analytical standard of Ketorolac (tromethamine salt). This product is intended for research and analytical applications. Ketorolac tromethamine salt (RS37619 tromethamine salt) is a non-steroidal anti-inflammatory agent, acting as a nonselective COX inhibitor, with IC50s of 20 nM for COX-1 and 120 nM for COX-2. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(S)-Ketorolac | 98.93% | (S)-Ketorolac is a nonsteroidal anti-inflammatory agent. (S)-ketorolac exhibits potent COX1 and COX2 enzyme inhibition. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(R)-Ketorolac | 99.35% | (R)-Ketorolac is an orally active Cdc42 and Rac1 inhibitor. (R)-Ketorolac inhibits GTPase. (R)-Ketorolac alters ovarian cancer cell behaviors critical for invasion and metastasis. (R)-Ketorolac ameliorates cancer-associated cachexia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ketorolac hydrochloride | Ketorolac (RS37619) hydrochloride is a non-steroidal anti-inflammatory drug (NSAID), acting as a nonselective COX inhibitor, with IC50s of 20 nM for COX-1 and 120 nM for COX-2. Ketorolac hydrochloride tromethamine is used as 0.5% ophthalmic solution for the research of allergic conjunctivitis, cystoid macular edema, intraoperative miosis, and postoperative ocular inflammation and pain. Ketorolac hydrochloride tromethamine is also a DDX3 inhibitor that can be used for cancer research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tolmetin | 99.54% | Tolmetin is an orally active and potent COX inhibitor with IC50s of 0.35 μM and 0.82 μM human COX-1 and COX-2, respectively. Tolmetin is a non-steroidal anti-inflammatory drug (NSAID). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tolmetin-d3 | 99.02% | Tolmetin-d3 is the deuterium labeled Tolmetin. Tolmetin is an orally active and potent COX inhibitor with IC50s of 0.35 μM and 0.82 μM human COX-1 and COX-2, respectively. Tolmetin is a non-steroidal anti-inflammatory drug (NSAID). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
2-(4-Chlorobenzoyl)benzoic acid-d4 | 2-(4-Chlorobenzoyl)benzoic acid-d4 is the deuterium labeled 2-(4-Chlorobenzoyl)benzoic acid (HY-W008737). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(4-Nitrophenyl)(phenyl)methanone-d5 | (4-Nitrophenyl)(phenyl)methanone-d5 is the deuterium labeled (4-Nitrophenyl)(phenyl)methanone. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
2,4′-Dihydroxybenzophenone-d5 | (2,4-Dihydroxyphenyl)(phenyl)methanone-d5 is the deuterium labeled (2,4-Dihydroxyphenyl)(phenyl)methanone. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Oxindanac | Oxindanac is a nonsteroidal anti-inflammatory agent. Oxindanac produces inhibition of serum TxB2 production. Oxindanac reduces the volume of swelling. Oxindanac shows analgesic activity. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Waterbury LD, et al. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40. [Content Brief]
- [4]. Samal SK, et al. Ketorolac salt is a newly discovered DDX3 inhibitor to treat oral cancer. Sci Rep. 2015 Apr 28;5:9982. [Content Brief]
